Pfizer has apparently found a new use for a drug that was yanked from the marketplace last year because of the risk of death, and now they want US regulators at the FDA to give the drug another chance.
Mylotarg had been on the market for 10 years until 2010, when the FDA asked Pfizer to stop selling it when a clinical trial showed that acute myeloid leukemia patients aged 60 or older, for whom the drug was indicated, were dying from liver complications.
According to an abstract presented at the recent ASH meeting in San Diego, patients with newly diagnosed acute myeloid leukemia given Mylotarg with chemotherapy lived for 25 months after treatment, compared with 15 months for those given chemotherapy alone.
This is the benefit that Pfizer hopes will resurrect Mylotarg back to the US market.
Source: Business Week
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
